Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis

Allergy and Asthma Proceedings

Volumn 28, Issue 2, 2007, Pages 145-152

  Blaiss, Michael S ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Allergy and Asthma Care   (United States)

Author keywords

Allergic rhinitis; Asthma; Cataracts; Ciclesonide; Cortisol suppression; Glaucoma; Growth; HPA axis; Systemic safety

Indexed keywords

ANTIALLERGIC AGENT; CORTICOSTEROID; HYDROCORTISONE;

ARTICLE; ASTHMA; BONE; CATARACT; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COMORBIDITY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG MONITORING; GLAUCOMA; HAY FEVER; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PERENNIAL RHINITIS; POLYPHARMACY; UNITED STATES;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ASTHMA; BONE AND BONES; CATARACT; CHRONIC DISEASE; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GLAUCOMA; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; POLYPHARMACY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES;

EID: 34248374818     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.2948     Document Type: Article

References (68)

1. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108(suppl):S2-S8, 2001.
2. Salib RJ, Drake-Lee A, and Howarth PH. Allergic rhinitis: Past, present and the future. Clin Otolaryngol Allied Sci 28:291-303, 2003.
3. Fineman SM. The burden of allergic rhinitis: Beyond dollars and cents. Ann Allergy Asthma Immunol 88(suppl):2-7, 2002.
4. Law A, Reed SD, Sundy JS, et al. Direct costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 111:296-300, 2003.
5. Thompson AK, Juniper E, and Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85:338-347, 2000.
6. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol. 108(suppl):S9-S15, 2001.
7. Bloebaum R. Managing allergic rhinitis: The role of pharmacotherapy; sound treatment can improve your patient's quality of life. J Respir Dis 23:370-376, 2002.
8. Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 27:883-898, 2004.
9. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 102:598-604, 1998.
10. Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: Safety aspects. Allergy 55:16-33, 2000.
11. Allen DB. Do intranasal corticosteroids affect childhood growth? Allergy 62:15-18, 2000.
12. Murphy K, Uryniak T, Simpson B, et al. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 96: 723-730, 2006.
13. Moller C, Ahlstrom H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 33:816-822, 2003.
14. Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol 108(suppl):S26-S31, 2001.
15. Lipworth BJ, and Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 52:476-482, 1997.
16. Juniper EF, Stahl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 115:S390-S413, 2005.
17. Trangsrud AJ, Whitaker AL, and Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 22:1458-1467, 2002.
18. Cervin A, Hansson C, Greiff L, et al. Nasal septal perforations during treatment with topical nasal glucocorticosteroids are generally not associated with contact allergy to steroids. ORL J Otorhinolaryngol Relat Spec 65:103-105, 2003.
19. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergie rhinitis patients. Ann Allergy Asthma Immunol 77:153-160, 1996.
20. Mandl M, Nolop K, and Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol 79:370-378, 1997.
21. Greenbaum J, Leznoff A, Schulz J, et al. Comparative tolerability of two formulations of Rhinalar (flunisolide) nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 61:305-310, 1988.
22. Waddell AN, Patel SK, Toma AG, et al. Intranasal steroid sprays in the treatment of rhinitis: Is one better than another? J Laryngol Otol 117:843-845, 2003.
23. Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol 91:44-48, 2003.
24. Ratner PH, Rowland WC III, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 90:536-542, 2003.
25. Galant SR, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 112:96-100, 2003.
26. AstraZeneca LP. Rhinocort Aqua (budesonide) Nasal Spray 32 meg prescribing information. Wilmington, DE; 2001, revised Jan. 2005.
27. Bende M, Carrillo T, Vóna I, et al. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 88:617-623, 2002.
28. Kobayashi RH, Beaucher WN, Koepke JW, et al. Triamcinolone acetonide aqueous nasal spray for the treatment of patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 17:503-513, 1995.
29. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics, and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51:400-409, 2001.
30. Thorsson L, Borga O, and Edsbäcker S. Systemic availability of budesonide after nasal administration of three different formulations: Pressurized aerosol, aqueous pump spray, and powder. Br J Clin Pharmacol 47:619-624, 1999.
31. Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 60:265-268, 2004.
32. Edsbacker S, Andersson KE, and Ryrfeldt A. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 29:477-481, 1985.
33. Nave R, Wingertzahn MA, Brookman S, et al. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 46:461-467, 2006.
34. Wolthers OD, and Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 82:635-640, 1993.
35. Wolthers OD, and Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 49:96-99, 1994.
36. Meltzer EO. Intranasal steroids: Managing allergic rhinitis and tailoring treatment to patient preference. Allergy Asthma Proc 26:445-451, 2005.
37. Boner AL. Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. J Allergy Clin Immunol 108(suppl):S32-S39, 2001.
38. Skoner D, Gentile D, Andelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 90:56-62, 2003.
39. Wilson AM, McFarlane LC, and Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 101:470-474, 1998.
40. Kim KT, Rabinovitch N, Uryniak T, et al. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 93:61-67, 2004.
41. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 165:1377-1383, 2002.
42. Goldberg S, Algur N, Levi M, et al. Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device, Ann Allergy Asthma Immunol 76:234-238, 1996.
43. Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 128:70-77, 2005.
44. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94:465-472, 2005.
45. Agertoft L, and Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115:940-945, 2005.
46. Pedersen S, Garcia Garcia ML, Manjra AI, et al. A comparative study of inhaled ciclesonide 160 ug/day and fluticasone 176 ug/ day in children with asthma. Pediatr Pulmonol. 41:954-961, 2006.
47. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 18:328-336, 2005.
48. Casale TB, and Dykewicz MS. Clinical implications of the allergic rhinitis-asthma link. Am J Med Sci 327:127-138, 2004.
49. Nayak AS. The asthma and allergic rhinitis link. Allergy Asthma Proc 24:395-402, 2003.
50. Williams DM. Clinical considerations in the use of inhaled corticosteroids for asthma. Pharmacotherapy 21:38S-48S, 2001.
51. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317: 1624-1629, 1998.
52. Adams RJ, Fuhlbrigge AL, Finkelstein JA, et al. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 109:636-642, 2002.
53. Sheth KK, Cook CK, Philpot EE, et al. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary- adrenal-axis function. Allergy Asthma Proc 25:115-120, 2004.
54. Wilson AM, and Lipworth BJ. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 54:20-26, 1999.
55. Weiner P, Berar-Yanay N, Davidovich A, et al. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 116:931-934, 1999.
56. Ratner P, Wingertzahn M, Hall N, et al. Effects of coadministration of intranasal ciclesonide (CIC) and inhaled beclomethasone dipropionate (BDP) on cortisol suppression. J Allergy Clin Immunol 2006:5259 (Abs 1003).
57. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 164:521-535, 2001.
58. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105:E23, 2000.
59. Agertoft L, and Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 104:948-952, 1999.
60. Allen DB, Meltzer EO, Lemanske RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 23:407-413, 2002.
61. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105:E22, 2000.
62. Mansfield LE, and Mendoza CP. Medium and long-term growth in children receiving intranasal beclomethasone dipropionate: A clinical experience. South Med J 95:334-340, 2002.
63. von Berg A, Garcia MHS, and Bethke T. Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. J Allergy Clin Immunol 117: S11, 2006 (Abs 42).
64. Skoner D, Maspero J, Kundu S, et al. Ciclesonide, administered once daily, has no effect on growth velocity in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol 117:311, 2006 (Abs 44).
65. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: Position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 96:1-12, 2006.
66. Bui CM, Chen H, Shyr Y, et al. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 116:1042-1047, 2005.
67. Opatowsky I, Feldman RM, Gross R, et al. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 102:177-179, 1995.
68. Chervinsky P, Kunjibettu S, Hampel FC, et al. Long-term safety of ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Presented at the Allergy, Asthma, and Immunology Annual Scientific Meeting, Philadelphia, Pennsylvania, November 9-15, 2006.